

Join one of the world's leading centres for cancer drug discovery



The Institute of Cancer Research, London, is making a significant investment in the ICR's Division of Cancer Therapeutics with the appointment of five new senior Faculty. Led by Dr Olivia Rossanese, Cancer Therapeutics implements innovative drug discovery technologies, discovers novel mechanism-based drugs, and develops these as rapidly as possible from the lab to hypothesis-testing clinical trials.

Based in a new state-of-the-art laboratory building on our Sutton Campus, the Division includes the Cancer Centre for Drug Discovery, the new Centre for Protein Degradation and the new Centre for Target Validation.

The Centre for Cancer Drug Discovery (CCDD) is a multidisciplinary 'bench to bedside' centre, comprising 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer.

We are one of the largest academic cancer drug discovery groups in the world and, together with our collaborators, have discovered 21 preclinical development candidates, 13 of which have been progressed to clinical evaluation, many with our partners in the ICR/Royal Marsden Drug Development Unit.

Our drug abiraterone (Zytiga) has been approved in the US, Canada and Europe for late-stage prostate cancer and has benefited hundreds of thousands of patients across the world.

The Centre for Protein Degradation (CPD), funded by a £9m philanthropic donation, will accelerate research into drug discovery using targeted protein degradation.

The Centre's scientists apply a wide range of protein degradation technologies to benefit fundamental discovery science and translational research across the ICR.

The Centre's dedicated resources, including chemistry, biology, structural biology and in silico science teams, will provide a nucleus for other ICR teams to collaborate with, bringing their specialist biological and clinical knowledge to enable the exploration of therapeutic protein degradation in the widest possible range of cancers.

The recently-established Centre for Target Validation (CTV) links the Division of Cancer Therapeutics and partner Divisions that identify potential drug targets, to accelerate the translation of ICR and collaborator research into successful drug discovery projects.

The Centre will identify candidate targets from across the wide spectrum of ICR laboratories and carry out in-depth therapeutic target validation to inform the launch of successful drug discovery projects.

Within the Breast Cancer Now Research Centre and Centre for Target Validation, we have also established the Breast Cancer Drug Target Validation Laboratory whose mission will be to identify and validate targets relevant in breast cancer and other malignancies.

See overleaf for details of the new senior scientific roles

Director, Centre of Protein Degradation

Head of Biology/ Director Centre for Target Validation

Breast Cancer Target Validation Team Leader/Deputy Director Centre for Target Validation

Computational Science Team Leader

Job details



Director, Centre for Protein Degradation ([click here for full details](#))

Will lead the conception and implementation of collaborative multi-disciplinary projects, coordinating the research of the expert medicinal chemistry, computational chemistry and biology, assay biology, DMPK, pharmacology and structural biology teams participating in the Centre. As a Team Leader, the Director will lead their own team of researchers in an area of chemical biology or chemistry relevant to protein degradation and contributing to the Centre's objectives.

Head of Biology/Director, Centre for Target Validation ([click here for full details](#))

Will provide scientific leadership for the CCDD biology discipline, champion scientific excellence, and work closely with senior team leaders in the CCDD to provide strategic vision for the research and drug discovery portfolio. As CTV Director, will collaborate with scientists across the ICR to identify target validation projects with therapeutic potential that are suitable to benefit from the Centre's dedicated resource and scientific expertise. Working with the CTV Deputy Director, will ensure that ICR expertise in drug target identification is effectively translated to drug discovery programmes at ICR and with external partners.

Breast Cancer Target Validation Team Leader/Deputy Director, Centre for Target Validation ([click here for full details](#))

A tenured laboratory Team Leader (Senior Scientist) to lead the ICR's efforts on the validation of cancer drug targets in the context of the Breast Cancer Now Toby Robins Research Centre. The appointed individual will also have the role of Deputy Director of the new Centre for Target Validation, where they will work with the CTV Director to identify candidate targets from across the wide spectrum of ICR laboratories and carry out in-depth therapeutic target validation to inform the launch of successful drug discovery projects.

Computational Science Team Leader

Will lead the application of computational biology to support and expand the oncology drug discovery portfolio and will also pursue their own oncology computational biology research aligned with the overall research strategy. Experience of drug discovery is highly desirable.

Informal enquiries

For informal enquiries about these roles please email Selina Mote, Executive Assistant to Dr Olivia Rossanese, at selina.mote@icr.ac.uk.

We welcome applications from all qualified candidates; researchers from groups underrepresented at the scientific leadership level are especially encouraged to apply.